145 related articles for article (PubMed ID: 16365543)
1. 3 cases of aberrant wound healing in acute myelogenous leukemia.
Smith L; Gallison B; Siegler EL
Adv Skin Wound Care; 2005; 18(9):473-6. PubMed ID: 16365543
[No Abstract] [Full Text] [Related]
2. How growth factors help chronic wounds heal.
Barry M
Nursing; 2000 May; 30(5):52-3. PubMed ID: 10855193
[No Abstract] [Full Text] [Related]
3. Original articles: ease of wound closure as an endpoint of treatment efficacy.
Robson MC; Maggi SP; Smith PD; Wassermann RJ; Mosiello GC; Hill DP; Cooper DM
Wound Repair Regen; 1999; 7(2):90-6. PubMed ID: 10231510
[TBL] [Abstract][Full Text] [Related]
4. Use of becaplermin gel and Kollagen Medifil particles.
Tomaselli NL
J Wound Ostomy Continence Nurs; 2000 Nov; 27(6):319-20. PubMed ID: 11096412
[No Abstract] [Full Text] [Related]
5. Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebo-controlled study.
Rees RS; Robson MC; Smiell JM; Perry BH
Wound Repair Regen; 1999; 7(3):141-7. PubMed ID: 10417749
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of becaplermin for nonhealing neuropathic diabetic foot ulcers.
Sibbald RG; Torrance G; Hux M; Attard C; Milkovich N
Ostomy Wound Manage; 2003 Nov; 49(11):76-84. PubMed ID: 14652415
[TBL] [Abstract][Full Text] [Related]
7. Clinical efficacy of becaplermin (rhPDGF-BB) gel. Becaplermin Gel Studies Group.
Wieman TJ
Am J Surg; 1998 Aug; 176(2A Suppl):74S-79S. PubMed ID: 9777976
[TBL] [Abstract][Full Text] [Related]
8. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers.
Nagai MK; Embil JM
Expert Opin Biol Ther; 2002 Feb; 2(2):211-8. PubMed ID: 11849120
[TBL] [Abstract][Full Text] [Related]
9. Use of becaplermin in progressive limb-threatening pyoderma gangrenosum.
Freedman BM; Oplinger EH
Adv Skin Wound Care; 2002; 15(4):180-2. PubMed ID: 12151984
[No Abstract] [Full Text] [Related]
10. Differential effects of platelet-derived growth factor BB in accelerating wound healing in aged versus young animals: the impact of tissue hypoxia.
Wu L; Brucker M; Gruskin E; Roth SI; Mustoe TA
Plast Reconstr Surg; 1997 Mar; 99(3):815-22; discussion 823-4. PubMed ID: 9047202
[TBL] [Abstract][Full Text] [Related]
11. Preclinical promise of becaplermin (rhPDGF-BB) in wound healing.
LeGrand EK
Am J Surg; 1998 Aug; 176(2A Suppl):48S-54S. PubMed ID: 9777972
[TBL] [Abstract][Full Text] [Related]
12. Use of Regranex gel for diabetic foot ulcers.
Piascik P
J Am Pharm Assoc (Wash); 1998; 38(5):628-30. PubMed ID: 9782698
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers. A phase III randomized placebo-controlled double-blind study.
Wieman TJ; Smiell JM; Su Y
Diabetes Care; 1998 May; 21(5):822-7. PubMed ID: 9589248
[TBL] [Abstract][Full Text] [Related]
14. Enhanced wound healing using topical recombinant human platelet-derived growth factor.
Seaman S
Nurse Pract; 2000 Oct; 25(10):85-9. PubMed ID: 11068780
[No Abstract] [Full Text] [Related]
15. Treatment of scleroderma skin ulcers using becaplermin gel and hydrocolloid membrane.
Yoon J; Giacopelli J; Granoff D; Kobayashi W
J Am Podiatr Med Assoc; 2002 Jun; 92(6):350-4. PubMed ID: 12070235
[TBL] [Abstract][Full Text] [Related]
16. Platelet-derived growth factor BB for the treatment of chronic pressure ulcers.
Robson MC; Phillips LG; Thomason A; Robson LE; Pierce GF
Lancet; 1992 Jan; 339(8784):23-5. PubMed ID: 1345953
[TBL] [Abstract][Full Text] [Related]
17. Use of becaplermin in the closure of pharyngocutaneous fistulas.
Jakubowicz DM; Smith RV
Head Neck; 2005 May; 27(5):433-8. PubMed ID: 15776464
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human platelet-derived growth factor-BB (becaplermin) for healing chronic lower extremity diabetic ulcers: an open-label clinical evaluation of efficacy.
Embil JM; Papp K; Sibbald G; Tousignant J; Smiell JM; Wong B; Lau CY
Wound Repair Regen; 2000; 8(3):162-8. PubMed ID: 10886806
[TBL] [Abstract][Full Text] [Related]
19. The nitric oxide connection: hyperbaric oxygen therapy, becaplermin, and diabetic ulcer management.
Boykin JV
Adv Skin Wound Care; 2000; 13(4 Pt 1):169-74. PubMed ID: 11075012
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies.
Smiell JM; Wieman TJ; Steed DL; Perry BH; Sampson AR; Schwab BH
Wound Repair Regen; 1999; 7(5):335-46. PubMed ID: 10564562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
